Cartesian Therapeutics Inc (NAS:RNAC)
$ 34.4 3.28 (10.43%) Market Cap: 612.18 Mil Enterprise Value: 466.55 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 46/100

Q3 2019 Selecta Biosciences Inc Earnings Call Transcript

Nov 08, 2019 / 01:30PM GMT
Release Date Price: $41.7 (-9.74%)
Operator

Good morning, and welcome to the Selecta Biosciences Third Quarter 2019 Financial Results Conference Call. (Operator Instructions) This call is being webcast live on the Investors and Media section of Selecta's website at www.selectabio.com and it is being recorded. For opening remarks, I would like to introduce Elona Kogan, General Counsel of Selecta. Please go ahead.

Elona Kogan
Selecta Biosciences, Inc. - General Counsel & Corporate Secretary

Thank you, and good morning, everyone. Welcome to our third quarter 2019 financial results and corporate update conference call. The press release reporting our financial results and the 10-Q, which we filed is available in the press release section of our website, www.selectabio.com. Joining me for today's call is Carsten Brunn, our President and Chief Executive Officer; Dr. Alison Schecter, our Chief Medical Officer; and Brad Dahms, our Chief Financial Officer. As a reminder, we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot